الابحاث

South Egypt Cancer Institute

Assiut University

Department of Pediatric Oncology
# Title Research Member Research Year
61 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Dr. Tarek Mohamed Abdel Moneim Mohamed Elsaba Ahmed 2018
62 Flowcytometric CD135 Expression
and its Impact on Pediatric Acute
Lymphoblastic Leukemia at South Egypt
Cancer Institute 		Dr. Azaa Shibl Sayed Mahmoud 2018
63 Flowcytometric CD135 Expression
and its Impact on Pediatric Acute
Lymphoblastic Leukemia at South Egypt
Cancer Institute 		Prof. Heba Abdel-Razik Sayed Hussein 2018
64 HCMV Among Pediatrics Acute Lymphoblastic Leukemia Patients in South Egypt Cancer Institute Dr. Khaled Fathy Riad Osman 2018
65 Nutritional Assessment and Intervention Methods in Children at Pediatric Oncology Department Mohammed Zakrya Ahmed Saleh 2018
66 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Dr. Samar Muhammad mansour 2018
67 Flowcytometric CD135 Expression
and its Impact on Pediatric Acute
Lymphoblastic Leukemia at South Egypt
Cancer Institute 		Prof. Heba Abdel-Razik Sayed Hussein 2018
68 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Dr. Shaimaa / Elsayyed Youssef / Ahmed 2018
69 Risk-Adapted, Combined-Modality Therapy for
Unfavorable Pediatric Hodgkin Lymphom 		Prof. Amany Mohamed Ali Ahmed 2018
70 Can Pediatric Risk of Mortality Score (PRISM III) Be Used Effectively in Initial Evaluation and Follow-up of Critically Ill Cancer Patients Admitted to Pediatric Oncology Intensive Care Unit (POICU)? A Prospective Study, in a Tertiary Cancer Center in Egy Prof. Heba Abdel-Razik Sayed Hussein 2017